BioNTech SE (BNTX) Common Equity (2018 - 2021)
Historic Common Equity for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $21.6 billion.
- BioNTech SE's Common Equity rose 290.14% to $21.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 billion, marking a year-over-year increase of 290.14%. This contributed to the annual value of $20.7 billion for FY2024, which is 477.78% down from last year.
- Per BioNTech SE's latest filing, its Common Equity stood at $21.6 billion for Q3 2025, which was up 290.14% from $20.9 billion recorded in Q2 2025.
- Over the past 5 years, BioNTech SE's Common Equity peaked at $21.8 billion during Q4 2023, and registered a low of $3.0 billion during Q1 2021.
- For the 5-year period, BioNTech SE's Common Equity averaged around $18.0 billion, with its median value being $20.5 billion (2024).
- In the last 5 years, BioNTech SE's Common Equity soared by 89588.49% in 2021 and then tumbled by 822.44% in 2025.
- BioNTech SE's Common Equity (Quarter) stood at $13.6 billion in 2021, then surged by 50.39% to $20.5 billion in 2022, then grew by 6.46% to $21.8 billion in 2023, then fell by 4.78% to $20.7 billion in 2024, then grew by 4.14% to $21.6 billion in 2025.
- Its Common Equity stands at $21.6 billion for Q3 2025, versus $20.9 billion for Q2 2025 and $19.9 billion for Q1 2025.